# Pheast Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/pheast-therapeutics

- Industry: Biotechnology
- Headquarters: Palo Alto, US
- Website: www.pheast.com
- Total disclosed funding: $76M
- Latest round: Series A (Apr 26, 2022)
- Investors on record: 4

## About

Based in California, US, and founded in 2020 by Amira Barkal, Pheast Therapeutics, Inc activates the immune system to pheast on cancer. In April 2022, Pheast Therapeutics, Inc. raised USD 76 million in series A funding co-led by new investors ARCH Venture Partners and Catalio Capital Management, with participation from other new investors Alexandria Venture Investments and Risk and Reward Group.

The company is focused on developing novel checkpoint therapies to harness the innate immune system in the fight against cancer. The firm has developed CD47 as a "don't eat me" signal and is critical to the advancement of CD47-targeting clinical programs to treat multiple hematologic malignancies. The company is targeting an entirely new signaling axis through their CD24 pipeline which has shown promise in animals for treating ovarian cancer, breast cancer, and other solid tumors. The company is also leveraging its proprietary discovery platform to enable the development of additional novel tumor-specific cancer immunotherapies.

The company will use the April 2022 funding to expand its management, science, and management teams, research and development, and send a pipeline of innate immune checkpoint inhibitors to the clinic.

## Funding rounds

- Series A, Apr 26, 2022, $76M — ARCH Venture Partners, Alexandria Venture Investments, Catalio Capital Management, Risk and Reward Group

## Investors

- ARCH Venture Partners (https://capitalatlas.ai/funds/arch-venture-partners) — Series A
- Alexandria Venture Investments (https://capitalatlas.ai/funds/alexandria-venture-investments) — Series A
- Catalio Capital Management (https://capitalatlas.ai/funds/catalio-capital-management) — Series A
- Risk and Reward Group — Series A